Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
Benzodiazepine anticonvulsant

Onfi (clobazam)

Also marketed as Sympazan. An approved treatment for Lennox-Gastaut Syndrome.

FDA Approved (2011)by Lundbeck (Onfi); Cosette Pharmaceuticals (Sympazan, made by Aquestive Therapeutics)
Preclinical
Phase 1
Phase 2
Phase 3
Approved
2011

Drug facts

The same compound appears under different names depending on the context. Here is how to identify Clobazam wherever you encounter it, plus the key facts at a glance.

Generic name
Clobazam
Brand names
Onfi, Sympazan
Drug class
Benzodiazepine anticonvulsant
Manufacturer
Lundbeck (Onfi); Cosette Pharmaceuticals (Sympazan, made by Aquestive Therapeutics)
How it's taken
By mouth: Onfi tablets or oral suspension, or Sympazan film dissolved on the tongue, once or twice a day

Clobazam is a benzodiazepine seizure medicine approved as an add-on treatment for seizures associated with Lennox-Gastaut syndrome in people 2 years and older[1][2].

  • Lundbeck sells it as Onfi tablets (10mg and 20mg) and Onfi oral suspension (2.5mg/mL), and Sympazan is a separate oral film (5mg, 10mg and 20mg) that dissolves on the tongue[1][2].
  • The FDA approved Onfi tablets on October 21, 2011, Onfi oral suspension on December 14, 2012 and Sympazan on November 1, 2018[3][4][5]. Both labels carry a boxed warning about use with opioids, abuse and addiction, and dependence and withdrawal, and clobazam is a Schedule IV controlled substance[1][2].
  • Generic clobazam tablets and oral suspension are FDA approved[6].
Follow Onfi by email

We'll email you when Onfi's FDA label changes, when the FDA acts on it, and when new trials for Lennox-Gastaut Syndrome open. Unsubscribe anytime.

You'll get, for Lennox-Gastaut Syndrome:
  • Trial Alerts, when a new trial opens or a trial changes
  • Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Turn either off anytime from the link in every email.

We never share your email. Unsubscribe anytime. Privacy policy · Check any health site

Where Clobazam fits

Clobazam (Onfi, Sympazan) is a benzodiazepine approved since 2011 as an add-on treatment for seizures associated with Lennox-Gastaut syndrome in people 2 years and older[1][3].

  • Lennox-Gastaut care usually combines several seizure medicines, and the clobazam trials enrolled people already taking others, most often valproate, lamotrigine, levetiracetam and topiramate[1].
  • Other medicines labeled for Lennox-Gastaut seizures include rufinamide (Banzel), cannabidiol (Epidiolex), fenfluramine (Fintepla), lamotrigine, topiramate, clonazepam (Klonopin) and felbamate (Felbatol)[15][13][14][18][17][16][19].
  • The clobazam labels report a trial against placebo and a trial of 2 clobazam doses, and ClinicalTrials.gov lists no Phase 3 trial comparing clobazam with another Lennox-Gastaut medicine[1][7].
  • The Epidiolex label says cannabidiol raises levels of N-desmethylclobazam, clobazam's active breakdown product, and suggests considering a lower clobazam dose if clobazam side effects appear[13].
  • Anyone considering clobazam can ask their neurologist how its sleepiness and dependence risks fit with their other seizure medicines, and whether a CYP2C19 gene result would change the starting dose.

How Clobazam works

Lennox-Gastaut syndrome causes several seizure types, including drop seizures (atonic, tonic or myoclonic seizures that can make a person fall). Clobazam belongs to the benzodiazepine family, and the label says it is thought to work by binding the benzodiazepine site of the GABA-A receptor, which strengthens GABA, the brain's main calming signal; the exact way it works is not fully understood[1].

The liver turns clobazam into an active breakdown product, N-desmethylclobazam, which reaches blood levels 3-5 times higher than clobazam itself at usual doses[1]. Clobazam lasts a long time in the body: the label gives average half-lives of 36-42 hours for clobazam and 71-82 hours for N-desmethylclobazam, and blood levels take 5 and 9 days to settle, which is why doses are raised no faster than once a week[1].

The liver enzyme CYP2C19 clears N-desmethylclobazam, so people who inherit a slow version of CYP2C19 build up higher levels[1][2]. Sympazan film was approved on studies showing it delivers the same clobazam levels as clobazam tablets at the same dose[2].

Side effects and safety

What patients report
Boxed warning
Both the Onfi and Sympazan labels warn that taking a benzodiazepine with an opioid can cause profound sedation, slowed breathing (respiratory depression), coma and death, so the combination is kept for people with no adequate alternative, at the lowest doses for the shortest time. They also warn that benzodiazepines carry risks of abuse, misuse and addiction that can lead to overdose or death, and that continued use can cause physical dependence, so stopping suddenly or cutting the dose fast can bring on life-threatening withdrawal; the dose is lowered with a gradual taper.
Label warnings
  • Use with opioids. profound sedation, slowed breathing, coma and death; prescribed together only when other options are inadequate, at the lowest doses for the shortest time
  • Abuse, misuse and addiction. the prescriber checks each person's risk before and during treatment; use with alcohol, other medicines or illicit drugs raises the risk of serious outcomes
  • Dependence and withdrawal. a gradual taper of 5-10mg a day each week to stop or lower the dose; a protracted withdrawal syndrome lasting weeks to more than 12 months has been reported with benzodiazepines
  • Sleepiness and sedation. dose-related, usually starting in the first month and sometimes easing; worse with alcohol or other sedating medicines; no driving or dangerous machinery until the effect is known
  • Serious skin reactions. Stevens-Johnson syndrome and toxic epidermal necrolysis in children and adults since approval, watched for most closely in the first 8 weeks or on restarting; clobazam is stopped at the first sign of rash unless it is clearly not drug-related
  • DRESS (multiorgan hypersensitivity). fever, rash, swollen glands or facial swelling with organ involvement such as hepatitis, which can be fatal; clobazam is stopped if no other cause is found
  • Suicidal thoughts or behavior. a warning shared by all seizure medicines; watch for new or worse depression or unusual mood or behavior changes
  • Pregnancy and newborns. use late in pregnancy can cause sedation or withdrawal symptoms in the newborn; clobazam passes into breast milk, and sleepiness and poor feeding have been reported in breastfed infants
  • Hormonal birth control. clobazam can make some hormonal contraceptives less effective, so the label recommends an added non-hormonal method
Most common in trials
Sleepiness or sedationFeverLethargyDroolingConstipationAggressionUpper respiratory infectionVomiting
What gets monitored
  • Watching for sleepiness and slowed breathing, most of all with opioids, alcohol or other sedating medicines
  • Skin checks for rash, most closely in the first 8 weeks or after restarting
  • Watching for mood changes or thoughts of self-harm
  • Screening for abuse, misuse and addiction risk before and during treatment
Report a suspected reaction to For Onfi, Lundbeck at 1-800-455-1141; for Sympazan, the number on its label, 1-800-518-1084; or FDA MedWatch at 1-800-FDA-1088, or to the FDA at 1-800-FDA-1088.
Side effects in the trial, Onfi against placebo
OnfiPlaceboShare of people in each group who reported it
Sleepiness or sedation
26%
15%
Fever
13%
3%
Upper respiratory infection
12%
10%
Lethargy
10%
5%
Drooling
9%
3%
Aggression
8%
5%
Vomiting
7%
5%
Constipation
5%
0%
Bars run from 0% to 30%. A side effect can be more common in the placebo group, which can happen when the symptom comes from the disease itself or by chance.
In context

The Onfi and Sympazan labels carry the same boxed warning: taking clobazam with opioids can cause profound sedation, slowed breathing, coma and death; benzodiazepines carry risks of abuse, misuse and addiction; and continued use can cause physical dependence, with life-threatening withdrawal if the medicine is stopped suddenly or cut quickly[1][2].

In the placebo-controlled Lennox-Gastaut trial (Study 1) of 179 people on clobazam and 59 on placebo, the most common side effects across all clobazam doses were sleepiness or sedation (26% against 15%), fever (13% against 3%), upper respiratory infection (12% against 10%), lethargy (10% against 5%), drooling (9% against 3%), aggression (8% against 5%), vomiting (7% against 5%) and constipation (5% against 0%)[1].

Side effects at least 10 points more common than placebo at some dose were constipation, sleepiness or sedation, fever, lethargy and drooling; sleepiness or sedation reached 32% on the highest dose[1]. The side effects that most often led people to stop were lethargy, sleepiness, unsteady walking (ataxia), aggression, fatigue and trouble sleeping[1].

Other label warnings cover serious skin reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis, a whole-body allergic reaction called DRESS, suicidal thoughts and behavior, and sedation or withdrawal in newborns exposed late in pregnancy[1][2]. Alcohol raises peak clobazam levels by about 50% and adds to its sedation[1].

This is not a complete list of side effects. Talk to your doctor or pharmacist about what to expect and when to seek medical attention.

Taking Clobazam

Onfi and Sympazan use the same weight-based schedule, taken by mouth with or without food[1][2]. People who weigh 30kg or less start at 5mg a day, go to 10mg a day from day 7 and to 20mg a day from day 14; people who weigh more than 30kg start at 10mg a day, then 20mg and 40mg on the same days[1]. Doses above 5mg a day are split into 2 doses, and the dose is raised no faster than once a week[1].

Each dose in the table worked in trials, and the label says effectiveness increases with dose, so the dose is set within each weight group by seizure control and how well it is tolerated[1].

People known to be CYP2C19 poor metabolizers, older adults, and people with mild or moderate liver impairment start at 5mg a day and go up slowly to half the table doses, with a further step to the full maximum (20mg or 40mg a day by weight) possible from day 21[1][2]. The label gives no dose for severe liver impairment, needs no change for mild or moderate kidney impairment, and has no experience with severe kidney disease[1].

Strong or moderate CYP2C19 blockers such as fluconazole, fluvoxamine, ticlopidine and omeprazole can raise N-desmethylclobazam levels and may call for a clobazam dose adjustment, and clobazam can raise levels of drugs cleared by CYP2D6[1]. Stopping or lowering the dose uses a taper of 5-10mg a day each week[1].

Forms differ by product. Onfi tablets come in 10mg and 20mg strengths with a score line and can be swallowed whole, broken in half or crushed into applesauce[1]. Onfi oral suspension is 2.5mg/mL in a 120mL berry-flavored bottle, shaken before each dose and measured with the oral syringe and bottle adapter supplied, and it is used within 90 days of opening[1].

Sympazan oral film comes in 5mg, 10mg and 20mg strips in single pouches; the film is placed on top of the tongue to stick and dissolve, without liquid, chewing, spitting or talking, and a second film for the same dose waits until the first has dissolved[2].

Availability and cost

Generic available

Generic versions may be available at a lower cost. Ask your pharmacist.

Why it costs what it costs

Neither label gives a price. Drugs@FDA lists 17 approved generic clobazam applications for tablets and oral suspension with prescription (marketed) status, while the Sympazan film has no approved generic[6][5]. Lundbeck offers an Onfi copay card and free trial, and Cosette offers a Sympazan copay card[10][11].

Help paying for Onfi

With private insurance, the drugmaker's copay card can lower what you pay for Onfi. Drugmaker copay cards can't be used with Medicare, Medicaid or TRICARE, but charity funds often can. Of the 3 charity funds for Lennox-Gastaut Syndrome, 2 were open on November 16, 2026. Pick your insurance below to see which offers fit you.

Your insurance
From the drugmaker
Onfi (Clobazam)
Some details not published
  • Copay help

    Onfi Copay Savings Program: commercially insured patients 2 and older whose copay is over $10 pay a minimum of $10 per 30-day prescription, with a maximum benefit of $600 per 30-day prescription. Not for Medicaid, Medicare, other government programs or self-pay patients. LoyaltyScript, 1-855-809-5818, Monday to Friday 8 AM to 8 PM ET.

    For: private insurance · source
  • Other support

    Onfi 14-day free trial voucher for eligible commercially insured patients, 1 voucher per patient, activated online with the copay card.

    For: private insurance · source
  • Copay help

    Sympazan Savings Program (Cosette): eligible patients 2 and older may pay as little as $0 per 30-day supply; a maximum savings limit applies but is not stated. Not for Medicare, Medicaid, other federal or state programs or cash-paying patients. Customer service 1-877-853-1312.

    For: private insurance · source

Good to know: Read on onfi.com and sympazan.com on November 19, 2026. Neither site describes a free-drug program for uninsured patients; Lundbeck's US patient assistance page covers only migraine therapies. Generic clobazam tablets and suspension are sold by many makers.

Checked on the drugmaker's official pages on November 19, 2026. Programs change; confirm with the program before you rely on it.

Charity funds for Lennox-Gastaut Syndrome

  • From a charity · NORD RareCare
    Lennox-Gastaut Syndrome Medical Assistance fund
    Open

    Pays for: Medical and medication costs.

    The foundation says: “Accepting new applications and re-enrollments for next year”
  • From a charity · NORD RareCare
    Lennox-Gastaut Syndrome Premium Copay Assistance fund
    Open

    Pays for: Insurance premiums and copays.

    The foundation says: “Accepting new applications and re-enrollments for next year”
Status as each foundation showed it on November 16, 2026.

Every program and charity fund for Lennox-Gastaut Syndrome →

More ways to get help paying for treatment →

Insurance said no? Your Insurer Denied a Rare Disease Drug and Fewer Than 1 in 100 People Appeal, So Here Is the Playbook · 14 min read

Clinical trial results

Study 1, the OV-1012 trial (NCT00518713), randomized 238 people aged 2 to 54 with Lennox-Gastaut syndrome to placebo or a low, medium or high clobazam dose set by weight, added to their other seizure medicines, most often valproate, lamotrigine, levetiracetam and topiramate[1][7]. After a 4-week baseline, a 3-week titration and 12 weeks of maintenance, all 3 doses cut weekly drop seizures more than placebo, and the effect rose with dose[1].

The trial's ClinicalTrials.gov results give mean drop seizure reductions of 41.2% on the low dose, 49.4% on the medium dose and 68.3% on the high dose, against 12.1% on placebo[7]. The published paper reports that 43.4%, 58.6% and 77.6% of people on the 3 doses had their drop seizures cut by at least half, against 31.6% on placebo, and the low dose's responder rate did not differ significantly from placebo[8].

The label found no sign that the effect wore off over the 3-month maintenance period[1]. Study 2 compared a high and a low dose in 68 people aged 2 to 25, and the median drop seizure reduction was 93% on the high dose against 29% on the low dose[1]. Sympazan's approval rests on these studies plus bioavailability studies showing the film matches clobazam tablets[2].

Development history

The FDA approved Onfi tablets for Lennox-Gastaut seizures on October 21, 2011 under NDA 202067, and Onfi oral suspension on December 14, 2012 under NDA 203993, both held by Lundbeck[3][4]. Drugs@FDA lists the 5mg Onfi tablet as discontinued, and the 10mg and 20mg tablets remain[3]. The first generic clobazam tablets and suspension were approved on October 22, 2018[6].

Sympazan oral film, made by Aquestive Therapeutics with its film technology, was approved on November 1, 2018 under NDA 210833[5][2]. Cosette Pharmaceuticals announced on April 8, 2026 that it had acquired the U.S. sales and distribution rights to Sympazan and 6 other products from Assertio, and Drugs@FDA now names Cosette as the application holder[9][5].

Both labels now carry the class boxed warning for benzodiazepines; the current Onfi label was revised in October 2026 and the current Sympazan label in March 2024[1][2].

Ask anything about Clobazam
AI-powered answers from clinical trial databases, FDA reports, and medical literature
Start withor ask

Explore Lennox-Gastaut Syndrome trials

Other Lennox-Gastaut Syndrome treatments

Common questions about Clobazam

▸What is Clobazam (Onfi)?

Clobazam is a benzodiazepine seizure medicine approved as an add-on treatment for seizures associated with Lennox-Gastaut syndrome in people 2 years and older[1][2]. Lundbeck sells it as Onfi tablets (10mg and 20mg) and Onfi oral suspension (2.5mg/mL), and Sympazan is a separate oral film (5mg, 10mg and 20mg) that dissolves on the tongue[1][2]. The FDA approved Onfi tablets on October 21, 2011, Onfi oral suspension on December 14, 2012 and Sympazan on November 1, 2018[3][4][5]. Both labels carry a boxed warning about use with opioids, abuse and addiction, and dependence and withdrawal, and clobazam is a Schedule IV controlled substance[1][2]. Generic clobazam tablets and oral suspension are FDA approved[6].

▸How does Clobazam work?

Lennox-Gastaut syndrome causes several seizure types, including drop seizures (atonic, tonic or myoclonic seizures that can make a person fall). Clobazam belongs to the benzodiazepine family, and the label says it is thought to work by binding the benzodiazepine site of the GABA-A receptor, which strengthens GABA, the brain's main calming signal; the exact way it works is not fully understood[1]. The liver turns clobazam into an active breakdown product, N-desmethylclobazam, which reaches blood levels 3-5 times higher than clobazam itself at usual doses[1]. Clobazam lasts a long time in the body: the label gives average half-lives of 36-42 hours for clobazam and 71-82 hours for N-desmethylclobazam, and blood levels take 5 and 9 days to settle, which is why doses are raised no faster than once a week[1]. The liver enzyme CYP2C19 clears N-desmethylclobazam, so people who inherit a slow version of CYP2C19 build up higher levels[1][2]. Sympazan film was approved on studies showing it delivers the same clobazam levels as clobazam tablets at the same dose[2].

▸What are the side effects of Clobazam?

The Onfi and Sympazan labels carry the same boxed warning: taking clobazam with opioids can cause profound sedation, slowed breathing, coma and death; benzodiazepines carry risks of abuse, misuse and addiction; and continued use can cause physical dependence, with life-threatening withdrawal if the medicine is stopped suddenly or cut quickly[1][2]. In the placebo-controlled Lennox-Gastaut trial (Study 1) of 179 people on clobazam and 59 on placebo, the most common side effects across all clobazam doses were sleepiness or sedation (26% against 15%), fever (13% against 3%), upper respiratory infection (12% against 10%), lethargy (10% against 5%), drooling (9% against 3%), aggression (8% against 5%), vomiting (7% against 5%) and constipation (5% against 0%)[1]. Side effects at least 10 points more common than placebo at some dose were constipation, sleepiness or sedation, fever, lethargy and drooling; sleepiness or sedation reached 32% on the highest dose[1]. The side effects that most often led people to stop were lethargy, sleepiness, unsteady walking (ataxia), aggression, fatigue and trouble sleeping[1]. Other label warnings cover serious skin reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis, a whole-body allergic reaction called DRESS, suicidal thoughts and behavior, and sedation or withdrawal in newborns exposed late in pregnancy[1][2]. Alcohol raises peak clobazam levels by about 50% and adds to its sedation[1].

▸How is Clobazam taken?

Onfi and Sympazan use the same weight-based schedule, taken by mouth with or without food[1][2]. People who weigh 30kg or less start at 5mg a day, go to 10mg a day from day 7 and to 20mg a day from day 14; people who weigh more than 30kg start at 10mg a day, then 20mg and 40mg on the same days[1]. Doses above 5mg a day are split into 2 doses, and the dose is raised no faster than once a week[1]. Each dose in the table worked in trials, and the label says effectiveness increases with dose, so the dose is set within each weight group by seizure control and how well it is tolerated[1].

People known to be CYP2C19 poor metabolizers, older adults, and people with mild or moderate liver impairment start at 5mg a day and go up slowly to half the table doses, with a further step to the full maximum (20mg or 40mg a day by weight) possible from day 21[1][2]. The label gives no dose for severe liver impairment, needs no change for mild or moderate kidney impairment, and has no experience with severe kidney disease[1]. Strong or moderate CYP2C19 blockers such as fluconazole, fluvoxamine, ticlopidine and omeprazole can raise N-desmethylclobazam levels and may call for a clobazam dose adjustment, and clobazam can raise levels of drugs cleared by CYP2D6[1]. Stopping or lowering the dose uses a taper of 5-10mg a day each week[1].

Forms differ by product. Onfi tablets come in 10mg and 20mg strengths with a score line and can be swallowed whole, broken in half or crushed into applesauce[1]. Onfi oral suspension is 2.5mg/mL in a 120mL berry-flavored bottle, shaken before each dose and measured with the oral syringe and bottle adapter supplied, and it is used within 90 days of opening[1]. Sympazan oral film comes in 5mg, 10mg and 20mg strips in single pouches; the film is placed on top of the tongue to stick and dissolve, without liquid, chewing, spitting or talking, and a second film for the same dose waits until the first has dissolved[2].

▸Is Clobazam FDA approved?

Yes. The FDA approved clobazam as Onfi tablets on October 21, 2011, Onfi oral suspension on December 14, 2012 and Sympazan oral film on November 1, 2018, each as an add-on treatment for seizures associated with Lennox-Gastaut syndrome in people 2 years and older.

Add-on only: the labels approve clobazam alongside other seizure medicines, and Lennox-Gastaut syndrome is the only use on either label.

Under 2: safety and effectiveness have not been established.

Generics: generic clobazam tablets and oral suspension are FDA approved; the Sympazan film has no approved generic.

Source: Onfi prescribing information and Drugs@FDA

▸What is the clobazam dose for Lennox-Gastaut syndrome?

The dose is set by weight: 5mg a day to start for people 30kg or less, rising to 10mg from day 7 and 20mg from day 14, and 10mg a day for people over 30kg, rising to 20mg and then 40mg on the same days[1].

Split doses: anything above 5mg a day is given in 2 doses.

Pace: increases come no faster than once a week, because clobazam and its active breakdown product take 5 and 9 days to settle in the blood.

Lower start: CYP2C19 poor metabolizers, older adults and people with mild or moderate liver impairment start at 5mg a day and go to half the table doses, with a possible step to the full maximum from day 21.

Stopping: the dose comes down 5-10mg a day each week.

Source: Onfi prescribing information

▸What is the difference between Onfi and Sympazan?

Onfi and Sympazan contain the same medicine, clobazam, with the same use and weight-based dose, but they are different products with separate labels[1][2].

Onfi tablets: 10mg and 20mg scored tablets that can be swallowed whole, broken in half or crushed into applesauce.

Onfi suspension: a 2.5mg/mL berry-flavored liquid measured with the supplied oral syringe, used within 90 days of opening.

Sympazan film: 5mg, 10mg and 20mg strips placed on the tongue to dissolve without liquid; one film at a time.

Evidence: Sympazan was approved on studies showing it gives the same clobazam levels as clobazam tablets.

Makers: Lundbeck markets Onfi; Cosette Pharmaceuticals holds Sympazan, which Aquestive Therapeutics manufactures.

Source: Onfi and Sympazan prescribing information

▸What are the side effects of clobazam?

In the placebo-controlled Lennox-Gastaut trial, the most common were sleepiness or sedation (26% against 15% on placebo), fever (13% against 3%), lethargy (10% against 5%) and drooling (9% against 3%)[1].

Boxed warning: risks with opioids, abuse and addiction, and dependence with possibly life-threatening withdrawal if stopped suddenly.

Skin: Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported; the label says to stop at the first sign of rash unless it is clearly not drug-related.

Other warnings: DRESS, suicidal thoughts, and sedation or withdrawal in newborns exposed late in pregnancy.

Alcohol: raises peak clobazam levels by about 50% and adds to sleepiness.

Source: Onfi prescribing information

▸Is clobazam a controlled substance?

Yes. The Onfi and Sympazan labels both say clobazam is a Schedule IV controlled substance[1][2].

Why: clobazam is a benzodiazepine, and the labels warn of abuse, misuse, addiction and physical dependence.

Stopping: the labels call for a gradual taper because sudden stopping can cause withdrawal, including seizures.

Source: Onfi prescribing information

▸Why does CYP2C19 matter for clobazam?

CYP2C19 is the liver enzyme that clears clobazam's active breakdown product, N-desmethylclobazam, so people with a slow version build up more of it[1][2].

How much: both the Onfi and Sympazan labels report about 5 times higher blood levels of N-desmethylclobazam in poor metabolizers.

Dose: known poor metabolizers start at 5mg a day and go to half the usual table doses, with a possible step to the full maximum from day 21.

Other medicines: strong or moderate CYP2C19 blockers such as fluconazole, fluvoxamine, ticlopidine and omeprazole can raise levels the same way.

Source: Onfi and Sympazan prescribing information

▸How well did clobazam work in Lennox-Gastaut syndrome?

In the OV-1012 trial of 238 people, all 3 clobazam doses cut weekly drop seizures more than placebo, and the effect grew with dose[1].

Mean reduction: 41.2% on the low dose, 49.4% on the medium dose and 68.3% on the high dose, against 12.1% on placebo, over 12 weeks of maintenance[7].

Half or more fewer drop seizures: 43.4%, 58.6% and 77.6% of people on the 3 doses, against 31.6% on placebo; the low dose did not differ significantly[8].

High against low dose: in Study 2 of 68 people, the median reduction was 93% against 29%.

Source: Onfi prescribing information and ClinicalTrials.gov NCT00518713

▸Is there a generic for Onfi?

Yes. Drugs@FDA lists 17 approved generic clobazam applications for tablets and oral suspension, the first approved on October 22, 2018[6].

Sympazan: the oral film has no approved generic.

Savings: Lundbeck's Onfi copay card lets eligible commercially insured patients pay as little as $10 per 30-day prescription, with a $600 maximum per prescription, and Cosette's Sympazan card offers as little as $0 per 30-day supply up to an unstated maximum; both exclude government plans.

Source: Drugs@FDA, Onfi savings and Sympazan savings

Sources and references

Every factual claim on this page is drawn from the public sources listed below. Click any reference to open the original document.

  1. Lundbeck Pharmaceuticals LLC via DailyMed · 2026-10-16. ONFI- clobazam tablet / ONFI- clobazam suspension. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de03bd69-2dca-459c-93b4-541fd3e9571c
  2. Aquestive Therapeutics via DailyMed · 2025-12-01. SYMPAZAN- clobazam film. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5e3d8fcb-aa7d-4822-88fc-4f06264c3242
  3. U.S. Food and Drug Administration · 2011-10-21. ONFI (clobazam) tablets, NDA 202067. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202067
  4. U.S. Food and Drug Administration · 2012-12-14. ONFI (clobazam) oral suspension, NDA 203993. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203993
  5. U.S. Food and Drug Administration · 2018-11-01. SYMPAZAN (clobazam) oral film, NDA 210833. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210833
  6. U.S. Food and Drug Administration (openFDA) · 2026-11-19. Drugs@FDA records for clobazam abbreviated new drug applications. https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name:%22CLOBAZAM%22+AND+application_number:ANDA*&limit=100
  7. ClinicalTrials.gov. Clobazam in Patients With Lennox-Gastaut Syndrome. https://clinicaltrials.gov/study/NCT00518713
  8. Neurology · 2011-10-11. Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome. https://pubmed.ncbi.nlm.nih.gov/21956725/
  9. Cosette Pharmaceuticals · 2026-04-08. Cosette Pharmaceuticals Expands Branded Portfolio through Acquisition of SYMPAZAN® and Additional Products from Assertio. https://cosettepharma.com/cosette-pharmaceuticals-expands-branded-portfolio-through-acquisition-of-sympazan-and-additional-products-from-assertio/
  10. Lundbeck. Onfi Savings, Resources and Support. https://www.onfi.com/onfi-savings-resources-and-support
  11. Cosette Pharmaceuticals. SYMPAZAN® (clobazam) Oral Film | SYMPAZAN Savings Program. https://sympazan.com/hcp/patient-savings/
  12. Biocodex, Inc. via DailyMed · 2026-04-27. DIACOMIT- stiripentol. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=58304ba8-9779-4658-811e-94ffe08c3f16
  13. Jazz Pharmaceuticals via DailyMed · 2026-05-29. EPIDIOLEX- cannabidiol solution. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8bf27097-4870-43fb-94f0-f3d0871d1eec
  14. UCB, Inc. via DailyMed · 2026-10-22. FINTEPLA- fenfluramine solution. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e88f360e-33ad-4cd6-b2de-5ef885857c5d
  15. Eisai Inc. via DailyMed · 2022-12-15. BANZEL- rufinamide. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0a3fa925-1abd-458a-bd57-4ae780a1ef2d
  16. H2-Pharma, LLC via DailyMed · 2025-12-01. KLONOPIN- clonazepam. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cfa0d79a-843c-4b88-95a1-e9511d649ca1
  17. Upsher-Smith Laboratories, LLC via DailyMed · 2026-09-03. QUDEXY XR- topiramate. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=46f54677-3a22-4c38-9b92-923020164e15
  18. OWP Pharmaceuticals, Inc. via DailyMed · 2026-08-26. SUBVENITE- lamotrigine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=022b0913-f683-4af8-a862-f81b315909b2
  19. Viatris Specialty LLC via DailyMed · 2025-08-15. FELBATOL- felbamate. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2f522701-397a-11de-8a39-0800200c9a66

This page is for informational purposes only and does not constitute medical advice. Drug information is sourced from public databases and peer-reviewed literature and may not reflect the most recent updates. Always discuss treatment options with your healthcare provider. Last reviewed: November 2026.

Follow Onfi by email

We'll email you when Onfi's FDA label changes, when the FDA acts on it, and when new trials for Lennox-Gastaut Syndrome open. Unsubscribe anytime.

You'll get, for Lennox-Gastaut Syndrome:
  • Trial Alerts, when a new trial opens or a trial changes
  • Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Turn either off anytime from the link in every email.
We never share your email. Unsubscribe anytime. Privacy policy · Check any health site